BTK and lymphoma: Nivocasan, an inhibitor of cellular caspases 1, 8, and 9 (treatment for hepatic fibrosis and non-alcoholic steatohepatitis related to HCV infection), as well as two inhibitors of Bruton’s tyrosine kinase (BTK; treatment for lymphoma and leukemia) were also inactive against SARS-CoV-2 with EC50 > 10 μM (Table 4).